Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

The field of off-the-shelf cell therapeutics is growing, with the promise of quicker, cheaper, and easier to manufacture therapies than the first generation of autologous CAR-Ts that impressed with their potency but fell short on adoption due to manufacturing wobbles. And Precision BioSciences — which is using its gene editing technology to develop cell based immunotherapies derived from healthy donors instead of the patient — is planning ahead. On Thursday, the company unveiled a new Durham, NC facility dedicated to making its off-the-shelf CAR-T products.